AC Immune SA (ACIU)
NASDAQ: ACIU · Real-Time Price · USD
3.030
+0.190 (6.69%)
Apr 28, 2026, 4:00 PM EDT - Market closed
AC Immune Revenue
In the year 2025, AC Immune had annual revenue of 3.57M CHF, down -86.92%. AC Immune had revenue of 338.00K in the quarter ending December 31, 2025, a decrease of -70.27%.
Revenue (ttm)
3.57M CHF
Revenue Growth
-86.92%
P/S Ratio
66.71
Revenue / Employee
29,287 CHF
Employees
122
Market Cap
300.58M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cellectis | 79.59M |
| Editas Medicine | 40.52M |
| Foghorn Therapeutics | 30.91M |
| Zentalis Pharmaceuticals | 26.87M |
| LENZ Therapeutics | 19.09M |
| Abeona Therapeutics | 5.82M |
| Inhibikase Therapeutics | 1.00 |
ACIU News
- 21 days ago - AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly - GlobeNewsWire
- 6 weeks ago - AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 4 months ago - AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's - Benzinga
- 4 months ago - AC Immune Transcript: Study Update - Transcripts
- 4 months ago - AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease - GlobeNewsWire
- 5 months ago - AC Immune Transcript: Jefferies London Healthcare Conference 2025 - Transcripts
- 6 months ago - AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 6 months ago - First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune's ACI-19626 in Precision Medicine - GlobeNewsWire